Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021

Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway, Harmony L. Tyner, Sarang K. Yoon, Jennifer Meece, Lauren E.W. Olsho, Alberto J. Caban-Martinez, Ashley Fowlkes, Karen Lutrick, Jennifer L. Kuntz, Kayan Dunnigan, Marilyn J. Odean, Kurt T. Hegmann, Elisha Stefanski, Laura J. Edwards, Natasha Schaefer-Solle, Lauren Grant, Katherine Ellingson, Holly C. GroomTnelda Zunie, Matthew S. Thiese, Lynn Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael E. Smith, Andrew L. Phillips, Kimberly D. Groover, Young M. Yoo, Joe Gerald, Rachel T. Brown, Meghan K. Herring, Gregory Joseph, Shawn Beitel, Tyler C. Morrill, Josephine Mak, Patrick Rivers, Katherine M. Harris, Danielle R. Hunt, Melissa L. Arvay, Preeta Kutty, Alicia M. Fry, Manjusha Gaglani

Research output: Contribution to journalArticlepeer-review

536 Scopus citations

Abstract

What is already known about this topic? Messenger RNA (mRNA) COVID-19 vaccines have been shown to be effective in preventing symptomatic SARS-CoV-2 infection in randomized placebo-controlled Phase III trials. What is added by this report? Prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of partial immunization (≥14 days after first dose but before second dose) was 80%. What are the implications for public health practice? Authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.

Original languageEnglish (US)
Pages (from-to)495-500
Number of pages6
JournalMorbidity and Mortality Weekly Report
Volume70
Issue number13
DOIs
StatePublished - 2021

ASJC Scopus subject areas

  • Epidemiology
  • Health(social science)
  • Health, Toxicology and Mutagenesis
  • Health Information Management

Fingerprint

Dive into the research topics of 'Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021'. Together they form a unique fingerprint.

Cite this